Baynes Roy D., an insider at Natera Inc (NTRA), sold 20,243 shares of the company stock on November 19, 2025, at a price of $223.90 per share, resulting in a total transaction value of $4.53 million. Following this sale, Baynes retains 20,243 shares in the company.
Natera, headquartered in Austin, Texas, is a biotechnology firm that specializes in genetic testing services. The company employs 4,424 full-time staff and has a market capitalization of $30.7 billion. Natera's innovative cfDNA technology platform integrates molecular biology techniques with bioinformatics and artificial intelligence, enabling the development of non-invasive prenatal tests and advanced cancer assays, among other offerings.
Insider transactions are reported to the SEC, providing transparency regarding executive perspectives on their company's stock. While this sale may attract attention, it is essential to consider that insider selling can occur for various reasons, including diversification and personal financial needs. Such decisions reflect individual circumstances rather than a definitive stance on the company's outlook.
Investors are advised to assess insider activity patterns over time and across multiple insiders, rather than focusing solely on isolated transactions. Natera's upcoming earnings report is scheduled for August 5, 2026, with an estimated EPS of -$0.54 and expected revenue of $637.8 million.